Horizon Pharma PLC (NASDAQ:HZNP) just disclosed third quarter of fiscal 2015 (3QFY15) results, before the markets opened today. The company reported a significant beat on both earnings and revenue expectations. It posted $0.7 in 3QFY15 earnings per share (EPS), which beat the consensus estimate of $0.41 by 70%.
The company generated $226.5 million in total quarterly revenue, which shows 202% year-over-year (YoY) growth, and also surpassed the consensus estimate of $193.14 million. The company attributed its strong revenues to significant growth in each of its business units, which include primary care, orphan, and specialty.
Horizon Pharma also increased its fiscal year 2015 (FY15) guidance, as it now sees revenue in the $750-760 million range, compared to prior expectations of $660-680 million. The new revenue guidance is significantly above the consensus estimate of $682.42 million. The company also increased FY15 earnings before interest, tax, depreciation, and amortization (EBITDA) guidance from $265-280 million to $350-360 million.